Effects of pemetrexed plus cisplatin on S100A9-myeloid derived suppressor cells versus docetaxel plus cisplatin in patients with non-small cell lung cancer

Trial Profile

Effects of pemetrexed plus cisplatin on S100A9-myeloid derived suppressor cells versus docetaxel plus cisplatin in patients with non-small cell lung cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2016

At a glance

  • Drugs Pemetrexed (Primary) ; Cisplatin; Docetaxel
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 20 Apr 2016 Results presented at the 107th Annual Meeting of the American Association for Cancer Research
    • 15 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top